The dogma of neuroregeneration has been that neurons cannot be repaired or replaced. NeuExcell's innovative technology challenges that doctrine and focuses on regenerating neural tissue. While neurons cannot divide to regenerate themselves, glial cells are a renewable source for generating neurons at the site of injury. Our AtN platform uses gene therapy to deliver specific transcription factors to glial cells in the brain, which converts these cells into functional and fully integrated neurons. We have generated proof of concept in rodents as well as in NHP with robust pre-clinical data for 3 lead indications, ischemic cortical stroke, Huntington's disease, and ALS. The first IND filing is anticipated by the end of 2023.
NeuExcell Formed at Penn State University Tech Incubator
NeuExcell Builds Management Team
$10+ Million Series Pre-A Round Raised
Partnership With Spark Therapeutics on Developing Gene Therapy for Huntington's Disease
Move to New Corporate Headquaters at Discovery Labs in King of Prussia, PA